Let's Get Clinical
Total Page:16
File Type:pdf, Size:1020Kb
10/21/19 1 Let’s Get Clinical: Addressing Metabolic Disease Functionally Melody L. Hartzler, PharmD, BCACP, BC-ADM Clinical Pharmacist, Western Medicine Family Physicians CEO, PharmToTable, LLC Associate Professor of Pharmacy Practice, Cedarville University School of Pharmacy 2 1 10/21/19 Disclosure There are no relevant financial relationshiPs with ACCME- defined commercial interests for anyone who was in control of the content of the activity. 3 Pharmacist and Pharmacy Technician Learning Objectives • Summarize the relationshiP between gut health and metabolic disease • Outline imPortant suPPlements for consideration in diabetic and Pre-diabetic populations • Identify the role of stress in diabetes and adrenal dysregulation 4 2 10/21/19 THIS SESSION WILL BE UTILIZING AUDIENCE POLLING SOFTWARE Please go to MEET.PS/CLINICAL to answer poll questions 5 Case: Mary • Mary is a 55 year old Caucasian female Presenting to your Pharmacist-run metabolic syndrome clinic • Here today to discuss her “diagnosis” of Prediabetes • Past medical history • SePsis 12 months ago (hospitalized for 2 weeks) • HTN • born via C-section • bottle fed with formula • frequent infections as a child 6 3 10/21/19 Case: Mary • Current History of Present Illness • Fatigue • Frequent yeast infections • Sedentary Lifestyle (works 8-10 hour days at a desk) • High stress job • TyPically follows a moderate intake of carbohydrate diet due to family history of diabetes • ConstiPation/Flatulence/Periodic Abdominal Pain 7 Case: Mary • Discuss with the Person next to you what your apProach for Mary would be today. 8 4 10/21/19 WHAT IS FUNCTIONAL MEDICINE? 9 Functional Medicine •Functional Medicine is a personalized, systems- oriented model that emPowers Patients and practitioners to achieve the highest expression of health by working in collaboration to address the underlying causes of disease. Jones D, Quinn S. Introduction to FM. 2014 10 5 10/21/19 7 Core Principles of FM • Acknowledging the biochemical individuality of each human being, based on concePts of genetic and environmental uniqueness • IncorPorating a Patient-centered aPProach to treatment • Seeking a dynamic balance among the internal and external factors in a patient’s body, mind, and spirit • Addressing the web-like interconnections of internal Physiological factors Jones D, Quinn S. Introduction to FM. 2014 11 7 Core Principles of FM • Identifying health as a Positive vitality—not merely the absence of disease—and emphasizing those factors that encourage a vigorous physiology • Promoting organ reserve as a means of enhancing the health span • Functional Medicine is a science-using profession Jones D, Quinn S. Introduction to FM. 2014 12 6 10/21/19 Nutrition Sedentary Aging Population Lifestyles Chronic Indoor Living Chronic Stress (Vitamin D) Disease Epidemic Fragmented Families & Poverty Communities Environmental Toxicity AdaPted from Jones D, Quinn S. Introduction to FM. 2014 13 One Condition Many Imbalances Inflammation Hormones Genetics and Epigenetics Diet and Exercise Mood Disorders Obesity AdaPted from Jones D, Quinn S. Introduction to FM. 2014 14 7 10/21/19 One Imbalance Heart Disease Many Conditions Diabetes Depression Inflammation Cancer Arthritis AdaPted from Jones D, Quinn S. Introduction to FM. 2014 15 Functional Strategies for Improving Cardiometabolic Resilience • Decrease central adiPosity • ImProve periPheral insulin sensitivity • Reduce inflammatory signaling • Reduce circulating free fatty acids • ImProve aPProPriate incretin signaling • Modulate inaPProPriate HPA-axis regulation & cortisol burden • Maintain/imProve kidney metabolic caPacity • Maintain circadian alignment Guilliams, T. Cardiometabolic Risk Management: A Functional and Lifestyle APProach. The Standard Road Map Series. Pointe Institute 2018. 16 8 10/21/19 Functional Strategies for Improving Cardiometabolic Resilience • Protect/imProve Pancreatic beta cell function • Reduce Post-prandial hyperinsulinemia (reduce meal impact) • Reduce liPoProtein atherogenicity • ImProve endothelial function • Reduce glycation and formation of accumulation AGEs • Modulate/balance coagulation caPacity • ImProve mitochondrial efficiency • Reduce oxidative burden • Restore metabolically-favorable gut microbiota Guilliams, T. Cardiometabolic Risk Management: A Functional and Lifestyle APProach. The Standard Road Map Series. Pointe Institute 2018. 17 Functional medicine approaches to address the underlying causes of metabolic disease • Address gut dysfunction • Improve insulin sensitivity • SuPPlements • Exercise (Enhances uPtake of glucose by Dr. Hartzler’s Peripheral tissues, DPP Trial) DM Protocol! • Diet • Address stress • Consider anti-inflammatory/cardiac risk reduction suPPlementation 18 9 10/21/19 Toxicities Related to Diabetes •Mercury exPosure1 •Persistent organic Pollutants2 1. He K, et al. Diabetes Care. 2013 Jun;36(6):1584-9 2. Lee D, et al. Diabetes Care. 2006;29(7):1638-1644 19 Egregious Eleven: defects present in diabetes and prediabetes AGI, alPha glucosidase inhibitor; GLP-1, glucagon-like PePtide 1; QR, quick release; TZDs, thiazolidinediones © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. Schwartz SS, Epstein S, Corkey BE, et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema. Diabetes Care Feb 2016, 39 (2) 179-186; DOI: 10.2337/dc15- 1585 20 10 10/21/19 Case: Mary • Mary is a 55 year old Caucasian female presenting to your Pharmacist-run metabolic syndrome clinic • She is here today to discuss her “diagnosis” of prediabetes • Past medical history • sePsis 12 months ago (hospitalized for 2 weeks) • HTN • born via C-section • bottle fed with formula • frequent infections as a child 21 Case: Mary • Current HPI • Fatigue • Frequent yeast infections • Sedentary Lifestyle (works 8-10 hour days at a desk) • High stress job • TyPically follows a moderate intake of carbohydrate diet due to family history of diabetes • ConstiPation/Flatulence/Periodic Abdominal Pain 22 11 10/21/19 Please go to MEET.PS/CLINICAL to answer Poll questions! 23 24 12 10/21/19 "All Disease Begins In The Gut." -Hippocrates METABOLIC DISEASE & THE GUT 26 Metabolic Syndrome • Metabolic syndrome is 3 of the following: • Increased waist circumference (>40 inches men, 35 women) • Elevated TG (>150 mg/dL) • Elevated BP (>130/80) • Elevated glucose • Low HDL-C (<40 mg/dL in men, <50 mg/dL in women) NCEP IV 2018 J Am Coll Cardiol. Nov 2018; DOI: 10.1016/j.jacc.2018.11.003 27 13 10/21/19 Metabolic Continuum & Type 2 Diabetes RePrinted with Permission: Figure 25. Guilliams, T. Cardiometabolic Risk Management: A Functional and Lifestyle Approach. The Standard Road Map Series. Pointe Institute 2018. 28 Insulin Resistance & CVD RePrinted with Permission: Figure 4. Guilliams, T. Cardiometabolic Risk Management: A Functional and Lifestyle Approach. The Standard Road Map Series. Pointe Institute 2018. 29 14 10/21/19 GIT Microbiome… an endocrine organ? Roles: Food - Carbohydrate digestion Intake - Hormone synthesis - Neurotransmitter production - Vitamin synthesis - Immune response modulation - Inflammatory response modulation Metabolism Energy GUT-BRAIN Homeostasis AXIS Galland L. J Med Food. 2014;17(12):1261-1272 Brown JM, et al. Annu Rev Med. 2015;66:343–359. 30 Metabolic Disease and the Gut- SCFAs • Short-chain fatty acids (SCFAs) are Produced by the fermentation of bacteria, when the bacteria in the colon metabolize Proteins and complex carbohydrates. • These SCFAs may decrease the risk of develoPing metabolic disorders due to the increasing demand of cholesterol for de novo synthesis of bile acids • SCFA Provide a direct energy source for colonocytes and as signaling molecules that influence ePigenetics Yoo JY et al. Nutrients. 2016 Mar; 8(3): 173. 31 15 10/21/19 Metabolic Disease and the Gut- SCFAs • SCFAs also are signaling molecules that Produce metabolic and satiety signaling comPounds such as: • Glucogon-like-pePtide-1 (GLP-1) • PePtide YY • SCFA can modulate insulin-signaling in adiPose tissue, Preventing fat accumulation. 1. Samuel BS et al. Pro Natl Acad Sci USA. 2008 Oct 28;105(43):16767-72. 2. Bolognini D, et al. Mol Pharmacol. 2016 Mar;89(3):388-98. 3. KimuraI et al. Nat Commun. 2013; 4:1829. 32 Metabolic Disease and the Gut- Microbiome Composition • Many persons with diabetes may be deficient in a sPecific gut microbe, bifidobacteria.1 • Having an imbalance of gut microbes can increase gut permeability and allow for infiltration of inflammatory signals which can cause damage to the Pancreas and contribute to the development of diabetes. 1. Gomes A, Bueno A, de Souza R, Mota J. Gut microbiota, Probiotics and diabetes. Nutr J. 2014;13:60. doi: 10.1186/1475-2891-13-60 33 16 10/21/19 Metabolic Disease and the Gut Microbiome & Immune Activation • LiPopolysaccharide (LPS) • Highly studied comPonent of gram-negative bacteria • Stimulates immunological responses • Stimulates Production of numerous inflammatory mediators • Leads to intestinal Permeability & chronic inflammation Creely SJ, et al. Am J Physiol Endrocrinol Metab. 2007 Mar; 292(3):E740-7. 34 Metabolic Disease and the Gut Microbiome & Immune Activation • This deficiency of bifidobacteria has been shown to result in increased translocation of bacterial liPopolysaccharide (LPS)9 which is thought to be a contributor to develoPment of insulin resistance.1 • SuPPlementation with